The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 28, 2012
Filed:
Sep. 08, 2008
Robert Edward Babine, Franklin, MA (US);
Shu-hui Chen, Carmel, IN (US);
Jason Eric Lamar, Indianapolis, IN (US);
Nancy June Snyder, Lizton, IN (US);
Xicheng Sun, Superior, CO (US);
Mark Joseph Tebbe, Hamburg, DE;
Frantz Victor, Indianapolis, IN (US);
Q. May Wang, Indianapolis, IN (US);
Yvonne Yee Mai Yip, Indianapolis, IN (US);
Ivan Collado, Madrid, ES;
Cristina Garcia-paredes, Madrid, ES;
Raymond Samuel Parker, Iii, Doylestown, PA (US);
Ling Jin, Carmel, IN (US);
Deqi Guo, Carmel, IN (US);
John Irvin Glass, Indianapolis, IN (US);
Robert Edward Babine, Franklin, MA (US);
Shu-Hui Chen, Carmel, IN (US);
Jason Eric Lamar, Indianapolis, IN (US);
Nancy June Snyder, Lizton, IN (US);
Xicheng Sun, Superior, CO (US);
Mark Joseph Tebbe, Hamburg, DE;
Frantz Victor, Indianapolis, IN (US);
Q. May Wang, Indianapolis, IN (US);
Yvonne Yee Mai Yip, Indianapolis, IN (US);
Ivan Collado, Madrid, ES;
Cristina Garcia-Paredes, Madrid, ES;
Raymond Samuel Parker, III, Doylestown, PA (US);
Ling Jin, Carmel, IN (US);
Deqi Guo, Carmel, IN (US);
John Irvin Glass, Indianapolis, IN (US);
Vertex Pharmaceuticals Incorporated, Cambridge, MA (US);
Abstract
The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.